Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients

• Published in: The journal of pathology. Clinical research Vol. 4; no. 4; pp. 262 - 273
• Main Authors: Dodson, Andrew, Parry, Suzanne, Ibrahim, Merdol, Bartlett, John MS, Pinder, Sarah, Dowsett, Mitch, Miller, Keith
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.10.2018
• Subjects: Age; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; clinical testing; Data entry; Databases, Factual; Epidermal growth factor; ErbB-2 protein; Estrogen Receptor alpha - genetics; Estrogen Receptor alpha - metabolism; external quality assessment; Female; HER2; human epidermal growth factor receptor‐2; Humans; Hybridization; Immunocytochemistry; Immunohistochemistry; In Situ Hybridization; Invasiveness; Ireland; Laboratories; oestrogen receptor; Original; Progesterone; progesterone receptor; Quality; Quality control; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Receptors, Progesterone - genetics; Receptors, Progesterone - metabolism; Software; Tumors; United Kingdom; Womens health; United Kingdom; Ireland; United Kingdom > UK; United States > US; PR; biomarkers; clinical testing; human epidermal growth factor receptor-2; breast cancer; external quality assessment; oestrogen receptor; HER2; ER; progesterone receptor

We describe a collated data set of results from clinical testing of breast cancers carried out between 2009 and 2016 in the United Kingdom and Republic of Ireland. More than 199 000 patient biomarker data sets, together with clinicopathological parameters were collected. Our analyses focused on huma...